Stock Analysis

Dr. Sulaiman Al Habib Medical Services Group Third Quarter 2024 Earnings: Beats Expectations

SASE:4013
Source: Shutterstock

Dr. Sulaiman Al Habib Medical Services Group (TADAWUL:4013) Third Quarter 2024 Results

Key Financial Results

  • Revenue: ر.س2.98b (up 22% from 3Q 2023).
  • Net income: ر.س595.5m (up 9.3% from 3Q 2023).
  • Profit margin: 20% (down from 22% in 3Q 2023). The decrease in margin was driven by higher expenses.
  • EPS: ر.س1.70 (up from ر.س1.56 in 3Q 2023).
earnings-and-revenue-growth
SASE:4013 Earnings and Revenue Growth November 5th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Dr. Sulaiman Al Habib Medical Services Group Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 9.6%. Earnings per share (EPS) also surpassed analyst estimates by 3.0%.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare industry in Saudi Arabia.

Performance of the Saudi Healthcare industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with Dr. Sulaiman Al Habib Medical Services Group (including 1 which is a bit unpleasant).

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.